Eyenovia
Yahoo Finance • 11 days ago
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue mark... Full story
Yahoo Finance • last month
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has e... Full story
Yahoo Finance • 2 months ago
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progre... Full story
Yahoo Finance • 2 months ago
Eyenovia Announces 1-for-80 Reverse Stock Split
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensi... Full story
Yahoo Finance • 7 months ago
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14%
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Basic Materials, Consumer Services and Industrials sectors led shares higher... Full story
Yahoo Finance • last year
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post o... Full story
Yahoo Finance • last year
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post o... Full story
Yahoo Finance • last year
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic te... Full story
Yahoo Finance • last year
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual M... Full story
Yahoo Finance • 2 years ago
Eyenovia Announces $12 Million Registered Direct Offering
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet®... Full story
Yahoo Finance • 2 years ago
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s Mydcombi sales force and represents addition... Full story
Yahoo Finance • 2 years ago
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing t... Full story
Yahoo Finance • 2 years ago
Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as... Full story
Yahoo Finance • 2 years ago
Eyenovia Announces Poster Presentation at ARVO 2023
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs f... Full story
Yahoo Finance • 2 years ago
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs... Full story
Yahoo Finance • 2 years ago
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs fo... Full story
Yahoo Finance • 2 years ago
Eyenovia (NASDAQ:EYEN) shareholders have endured a 69% loss from investing in the stock five years ago
It is a pleasure to report that the Eyenovia, Inc. (NASDAQ:EYEN) is up 57% in the last quarter. But that can't change the reality that over the longer term (five years), the returns have been really quite dismal. The share price has failed... Full story
Yahoo Finance • 2 years ago
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs fo... Full story
Yahoo Finance • 2 years ago
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs fo... Full story
Yahoo Finance • 2 years ago
Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used today has gone largely un... Full story
